Covid-19 manufacturing roundup: NY biotech primed to become ImmunityBio's drug substance goldmine; Illinois set to meet demand for at-home tests
A Buffalo, NY drug manufacturing site that was funded with $200 million of state money could soon become ImmunityBio’s largest manufacturer of Covid-19 vaccine drug substance by the end of the year.
The California biotech agreed to take over the lease from Athenex, a Buffalo biopharma. The site ran into a number of costly regulatory setbacks that delayed operations.
“We have great ambitions to make this plant our star plant, and really the idea is to build a campus around the plant and actually bring New York as our biological manufacturing hub,” executive chairman Patrick Soon-Shiong told The Buffalo News in an interview.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.